Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: Sept. 1, 2023
Prostate
cancer
(PCa)
is
a
serious
threat
to
the
health
of
men
all
over
world.
The
progression
PCa
varies
greatly
among
different
individuals.
In
clinical
practice,
some
patients
often
progress
advanced
PCa.
Therefore,
accurate
imaging
for
diagnosis
and
staging
particularly
important
management
patients.
Conventional
examinations
such
as
MRI
CT
cannot
accurately
diagnose
pathological
stages
PCa,
especially
metastatic
lymph
node
(LN)
stages.
As
result,
developing
an
molecular
targeted
crucial
specific
membrane
antigen
(PSMA)
great
value
in
because
its
expression
At
present,
researchers
have
developed
positron
emission
tomography
(PET)
targeting
PSMA.
A
large
number
studies
confirmed
that
it
not
only
has
higher
tumor
detection
rate,
but
also
diagnostic
efficacy
stage
compared
with
traditional
methods.
This
review
summarizes
recent
on
PSMA
PET
diagnosis,
analyzes
detail,
provides
new
ideas
urological
clinicians
management.
Critical Reviews in Oncology/Hematology,
Journal Year:
2024,
Volume and Issue:
205, P. 104556 - 104556
Published: Nov. 17, 2024
Prostate-specific
membrane
antigen
(PSMA)
is
one
of
the
few
biomarkers
which
has
been
successfully
translated
to
clinic
as
theranostic
biomarker
for
patients
with
prostate
cancer.
In
context
cancer,
PSMA
overexpressed
on
cell
tumor
cells,
making
it
a
viable
target
interventions
urea-based
small
molecule
inhibitors
or
antibodies
conjugated
radioactive
isotopes.
Interestingly,
in
several
non-prostatic
cancers,
expression
appears
be
associated
neovasculature.
This
offers
novel
therapeutic
opportunities
treatments
targeting
vasculature
cancers.
this
review,
we
discuss
and
its
potential
vasculature-directed
approaches,
including
radioligand
therapy,
fusion
protein
vaccination
CAR
T-cell
therapy.
Medicina,
Journal Year:
2023,
Volume and Issue:
59(6), P. 1144 - 1144
Published: June 14, 2023
At
the
time
of
diagnosis,
vast
majority
prostate
carcinoma
patients
have
a
clinically
localized
form
disease,
with
most
them
presenting
low-
or
intermediate-risk
cancer.
In
this
setting,
various
curative-intent
alternatives
are
available,
including
surgery,
external
beam
radiotherapy
and
brachytherapy.
Randomized
clinical
trials
demonstrated
that
moderate
hypofractionated
can
be
considered
as
valid
alternative
strategy
for
High-dose-rate
brachytherapy
administered
according
to
different
schedules.
Proton
represents
promising
strategy,
but
further
studies
needed
make
it
more
affordable
accessible.
moment,
new
technologies
such
MRI-guided
remain
in
early
stages,
their
potential
abilities
very
promising.
Zeitschrift für Naturforschung C,
Journal Year:
2024,
Volume and Issue:
79(9-10), P. 235 - 266
Published: May 29, 2024
Abstract
Theranostics
refers
to
the
combination
of
diagnostic
biomarkers
with
therapeutic
agents
that
share
a
specific
target
expressed
by
diseased
cells
and
tissues.
Nuclear
medicine
is
an
exciting
component
explored
for
its
applicability
in
theranostic
concepts
clinical
research
investigations.
theranostics
based
on
employment
radioactive
compounds
delivering
ionizing
radiation
diagnose
manage
certain
diseases
employing
binding
specifically
targets.
In
realm
personalized
medicine,
nuclear
stands
as
beacon
potential,
potentially
revolutionizing
disease
management.
Studies
exploring
profile
have
been
presented
this
review
along
detailed
explanation
their
several
diseases.
It
furnishes
insights
into
across
diverse
diseases,
elucidating
intricate
interplay
between
these
pathologies.
Light
shed
important
milestones
beginning
radioiodine
therapy
thyroid
carcinomas,
MIBG
labelled
iodine
neuroblastoma,
others.
Our
perspectives
put
forth
regarding
most
emerging
trends
prospects.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(17), P. 3039 - 3039
Published: Aug. 31, 2024
Prostate
cancer,
a
leading
cause
of
cancer-related
mortality
among
men,
is
characterized
by
complex
genetic
and
epigenetic
alterations,
dysregulation
oncogenic
pathways,
dynamic
tumor
microenvironment.
Advances
in
molecular
diagnostics
targeted
therapies
have
significantly
transformed
the
management
this
disease.
Prostate-specific
membrane
antigen
(PSMA)
has
emerged
as
critical
biomarker,
enhancing
precision
prostate
cancer
diagnosis
treatment.
Theranostics,
which
integrates
PSMA-targeted
imaging
with
radioligand
therapies,
shown
remarkable
efficacy
detecting
treating
advanced
cancer.
By
leveraging
dual
capabilities
PSMA-based
therapeutic
agents,
theranostics
offers
personalized
approach
that
improves
patient
outcomes.
This
comprehensive
review
explores
latest
developments
their
impact
on
future
management,
highlighting
key
clinical
trials
emerging
strategies.
OncoTargets and Therapy,
Journal Year:
2024,
Volume and Issue:
Volume 17, P. 991 - 1015
Published: Nov. 1, 2024
In
recent
years,
the
incidence
of
prostate
cancer
has
been
increasing
globally.
Early
stage
disease
can
obtain
a
better
clinical
prognosis
from
surgery
and
endocrine
therapy.
The
progression
advanced
varies
significantly
between
individuals,
with
some
patients
developing
metastatic
castration-resistant
after
standardized
treatment.
Therefore,
staging
by
accurate
imaging
is
particularly
important
for
management
patients.
Simultaneously,
development
targeted
therapy
also
urgent
treatment
cancer.
Prostate
specific
membrane
antigen
as
target
widely
used
in
diagnosis
This
review
summarizes
latest
research
progress
detail,
analyzes
their
value
challenges.
American Journal of Roentgenology,
Journal Year:
2022,
Volume and Issue:
220(5), P. 619 - 629
Published: Nov. 2, 2022
Theranostics
describes
the
coupling
of
a
diagnostic
biomarker
and
therapeutic
agent
(i.e.,
theranostic
pair)
that
have
common
target
in
tumor
cells
or
their
microenvironment.
The
term
is
increasingly
associated
with
vivo
nuclear
medicine
oncologic
applications
couple
imaging
by
means
gamma
radiation
concomitant
localized
high-energy
particulate
to
tissue
expressing
target.
Several
pairs
been
translated
into
clinical
practice
United
States
are
poised
become
mainstay
cancer
treatment.
purposes
this
article
review
experience
theranostics
for
solid-organ
malignancies
address
practical
integration
care
pathways
β-emitting
therapies
include
somatostatin
analogue
radioligands
neuroendocrine
tumors,
PSMA-directed
therapy
prostate
cancer,
Frontiers in Cell and Developmental Biology,
Journal Year:
2022,
Volume and Issue:
10
Published: Oct. 17, 2022
Chemoresistance
is
one
of
the
most
important
challenges
in
cancer
therapy.
The
presence
stem
cells
within
tumor
may
contribute
to
chemotherapy
resistance
since
these
express
high
levels
extrusion
pumps
and
xenobiotic
metabolizing
enzymes
that
inactivate
therapeutic
drug.
Despite
recent
advances
cell
metabolism
adaptations,
little
known
about
metabolic
adaptations
resistant
chemotherapy.
In
this
study,
we
have
undertaken
an
untargeted
metabolomic
analysis
by
liquid
chromatography–high-resolution
spectrometry
combined
with
cytotoxicity
assay,
western
blot,
quantitative
real-time
polymerase
chain
reaction
(qPCR),
fatty
acid
oxidation
a
prostate
line
antiandrogen
2-hydroxiflutamide
features
cells,
compared
its
parental
androgen-sensitive
line.
Metabolic
fingerprinting
revealed
106
out
850
metabolites
ESI+
67
446
ESI-
significant
differences
between
sensitive
lines.
Pathway
performed
unequivocally
identified
metabolites,
changes
pathways
involved
energy
as
well
posttranscriptional
regulation.
Validation
enzyme
expression
indicated
chemotherapy-resistant
were
metabolically
dormant
decreased
oxidation,
methionine
ADP-ribosylation.
Our
results
shed
light
on
underlying
entry
into
dormancy
might
mechanisms
drug
resistance.
Clinical Nuclear Medicine,
Journal Year:
2023,
Volume and Issue:
48(4), P. e163 - e164
Published: Jan. 14, 2023
Breast
cancer
in
men
is
a
rare
and
unsuspected
malignancy.
A
48-year-old
man
begins
with
disabling
low
back
pain.
The
CT
scan
reported
compression
fracture
L2
diffuse
skeletal
lesions
suggestive
of
metastatic
disease.
serum
prostate-specific
antigen
was
6.2
ng/mL.
He
referred
for
SPECT/CT
99m
Tc-EDDA/HYNIC-inhibitor
membrane
due
to
clinical
suspicion
prostate
cancer.
showed
primary
lesion
the
left
breast
multiple
bone
lesions.
Biopsy
confirmed
infiltrating
ductal
carcinoma
positive
hormone
receptors
indeterminate
HER2
(human
epidermal
growth
factor
receptor
2).
Letters in Oncology Science,
Journal Year:
2023,
Volume and Issue:
20(1)
Published: July 18, 2023
Rolą
teranostyki
jest
indywidualizacja
postępowania
diagnostycznego
i
leczniczego.
Obecnie
teranostyka
znajduje
najszersze
zastosowanie
w
monitorowaniu
leczeniu
guzów
neuroendokrynnych
raka
stercza.
Istotą
dobór
wskaźników
preparatów
radiofarmaceutycznych,
umożliwiających
obrazowanie
leczenie
choroby.
Wśród
wyjątkowych
teranostyce
radioizotopów,
dodatkowo
należy
lutet-177
aktyn-225.
